in 25 patients with cervical , uterine and ovarian cancer with a depletion of t-helper cells and a lack of reactivity in the lmi-test a course of immunotherapy with thymopentin ( timunox , cilag biotech ) at a dosage of 100 mg/die for 2 weeks and subsequently 100 mg 3 x/week for 4 weeks was performed and a comparison was made with a control group of 59 patients receiving no immunotherapy .
C0080225
thymopentin
C0918006
timunox